Back to News
Market Impact: 0.25
Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Inventiva (IVA) announced the last patient visit in its Phase 3 NATiV3 trial of lanifibranor for MASH with moderate to advanced fibrosis. While no efficacy or timing for topline results was provided, completing enrollment/progressing to late-stage readouts is a constructive clinical milestone. Overall, the update modestly improves sentiment toward the program’s potential.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IVEVF0.45
More News
- Dell (DELL) Q2 2027 Earnings Call Transcript
- Marvell shares have soared 241% in a year. CEO says this is a key reason why
- Palo Alto Networks (PANW) Q4 2026 Earnings Call Transcript
- MongoDB (MDB) Q2 2027 Earnings Call Transcript
- Credo (CRDO) Q1 2027 Earnings Call Transcript
- Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026